In: Multiple Sclerosis Journal, 28 (2022), Nr. 14. pp. 2294-2298. ISSN 1352-4585 (Druck-Ausg.); 1477-0970 (Online-Ausg.)
Preview |
PDF, English
- main document
Download (729kB) | Terms of use |
Abstract
We investigated the impact of disease-modifying therapies (DMTs) on the evolving tissue damage in iron rim multiple sclerosis lesions using a novel post-processing magnetic resonance imaging (MRI) approach, the T1/T2 ratio. In this study, on baseline and 1-year follow-up, T1/T2 ratios of iron rim lesions (IRLs) in patients starting DMT (dimethyl fumarate, fingolimod, ocrelizumab) did not statistically differ compared to patients without DMT. At the second follow-up, T1/T2 ratios were significantly lower in IRLs in patients without DMT (p = 0.002), suggesting that DMTs have a beneficial delayed effect on lesion evolution and tissue matrix damage in IRLs.
Document type: | Article |
---|---|
Journal or Publication Title: | Multiple Sclerosis Journal |
Volume: | 28 |
Number: | 14 |
Publisher: | Sage |
Place of Publication: | London |
Edition: | Zweitveröffentlichung |
Date Deposited: | 22 Feb 2023 08:05 |
Date: | 2022 |
ISSN: | 1352-4585 (Druck-Ausg.); 1477-0970 (Online-Ausg.) |
Page Range: | pp. 2294-2298 |
Faculties / Institutes: | Medizinische Fakultät Mannheim > Neurologische Klinik |
DDC-classification: | 610 Medical sciences Medicine |
Additional Information: | Dieser Beitrag ist aufgrund einer (DFG-geförderten) Allianz bzw. Nationallizenz frei zugänglich. *** This publication is freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively. |